Related Experiment Video
Updated: Aug 6, 2026
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Central nervous system involvement in acute lymphoblastic leukemia: pathogenesis and targeted therapy
Luke Quinlan1,2, David Yeung1,2,3,4, Susan Heatley2
1Blood Cancer Program, Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide, SA, Australia.
Leukemia
|July 17, 2026
Summary
Central nervous system involvement in acute lymphoblastic leukemia (ALL) poses challenges. Recent research clarifies CNS disease pathogenesis, focusing on leukemic cell persistence, microenvironment interactions, and therapeutic strategies for better outcomes.
Area of Science:
- Hematology
- Neuro-oncology
- Cancer Biology
Background:
- Central nervous system (CNS) involvement in acute lymphoblastic leukemia (ALL) is a severe complication linked to poor prognoses.
- Current diagnostic and therapeutic strategies for CNS ALL are hindered by an incomplete understanding of its pathogenesis.
- Recent research has significantly advanced the understanding of CNS disease mechanisms in ALL.
Purpose of the Study:
- To integrate recent findings on CNS infiltration and persistence mechanisms in ALL.
- To elucidate the signaling and metabolic pathways enabling leukemic cell survival and therapy resistance within the CNS.
- To evaluate novel therapeutic approaches and targeted therapies for CNS-directed treatment in ALL.
Main Methods:
- Review and integration of current research on CNS ALL pathogenesis.
- Analysis of studies detailing ALL cell infiltration and persistence mechanisms.
- Examination of research on the CNS microenvironment's role in leukemic cell survival and drug resistance.
Main Results:
- Understanding of CNS infiltration mechanisms by ALL cells has improved.
- The CNS microenvironment's role in ALL survival and therapy resistance is increasingly recognized, involving cell adhesion and metabolic reprogramming.
- Specific signaling and metabolic pathways conferring leukemic persistence have been identified.
Conclusions:
- Advances in understanding CNS ALL pathogenesis offer potential therapeutic targets.
- Targeting cell adhesion, metabolic reprogramming, and specific signaling pathways may overcome therapy resistance.
- Novel therapeutic avenues and targeted therapies show promise for enhancing CNS-directed treatment efficacy in ALL.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Cytotoxic T Cells-mediated Immune Response
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...